Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Releases FY 2024 Earnings Guidance

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) issued an update on its FY 2024 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 5.610-6.045 for the period. The company issued revenue guidance of $51.7 billion-$53.9 billion.

Analyst Ratings Changes

Separately, Bank of America raised Bayer Aktiengesellschaft from an “underperform” rating to a “neutral” rating in a research note on Friday, September 6th. One equities research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold”.

Bayer Aktiengesellschaft Trading Up 0.9 %

Shares of Bayer Aktiengesellschaft stock traded up $0.05 on Friday, reaching $5.41. The stock had a trading volume of 1,870,487 shares, compared to its average volume of 1,451,287. Bayer Aktiengesellschaft has a 1 year low of $5.33 and a 1 year high of $11.33. The company has a current ratio of 1.27, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04. The business’s 50 day moving average is $7.34 and its two-hundred day moving average is $7.41.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last announced its quarterly earnings data on Tuesday, November 12th. The company reported $0.07 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.10). The company had revenue of $10.96 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 2.02% and a positive return on equity of 16.46%. Equities analysts expect that Bayer Aktiengesellschaft will post 1.33 EPS for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.